Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene.
BACKGROUND
Familial partial lipodystrophy (FPLD) is a monogenic form of diabetes characterised by a dominantly inherited disorder of adipose tissue associated with the loss of subcutaneous fat from the limbs and trunk, with excess fat deposited around the face and neck. The lipodystrophy causes severe insulin resistance, resulting in acanthosis nigricans, diabetes, dyslipidaemia, and increased risk of cardiovascular disease. Preliminary results from animals and man suggest that increasing subcutaneous fat by treatment with thiazolidinediones should improve insulin resistance and the associated features of this syndrome.


METHODS
We report a 24-year-old patient with FPLD caused by a mutation in the LMNA gene (R482W) treated with 12 months of rosiglitazone. Subcutaneous fat increased following rosiglitazone treatment as demonstrated by a 29% generalised increase in skin-fold thickness. Leptin levels increased from 5.8 to 11.2 ng/ml. Compared with treatment on Metformin, there was an increase in insulin sensitivity (HOMA S% 17.2-31.6) but no change in glycaemic control. The lipid profile worsened during the follow-up period.


CONCLUSIONS
This initial case suggests that, for modification of cardiovascular risk factors, there are no clear advantages in treating patients with FPLD with rosiglitazone despite increases in subcutaneous adipose tissue. Larger series will be needed to identify moderate beneficial effects and treatment may be more effective in patients with generalised forms of lipodystrophy.
D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D003923:Diabetes Mellitus, Lipoatrophic / Q000097:blood / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D034904:Lamin Type A / Q000235:genetics*; D020738:Leptin / Q000097:blood; D009154:Mutation; D018160:Receptors, Cytoplasmic and Nuclear / Q000037:antagonists & inhibitors*; D000077154:Rosiglitazone; D012885:Skinfold Thickness; D045162:Thiazolidinediones / Q000627:therapeutic use*; D014157:Transcription Factors / Q000037:antagonists & inhibitors*
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D034904:Lamin Type A; D020738:Leptin; D018160:Receptors, Cytoplasmic and Nuclear; D000077154:Rosiglitazone; D045162:Thiazolidinediones; D014157:Transcription Factors; C440308:lamin C